vs
NVE CORP（NVEC）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是NVE CORP的1.5倍（$9.1M vs $6.2M），NVE CORP净利率更高（54.4% vs -60.3%，领先114.7%），NVE CORP同比增速更快（22.9% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-4.8M），过去两年NVE CORP的营收复合增速更高（-6.3% vs -6.7%）
NVE公司是一家专注于自旋电子元件研发和生产的科技企业，核心产品包括磁阻传感器、耦合器及信号隔离器，广泛应用于工业自动化、汽车电子、医疗设备及物联网领域，客户覆盖全球多家原始设备制造商与电子元件分销商。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
NVEC vs PLX — 直观对比
营收规模更大
PLX
是对方的1.5倍
$6.2M
营收增速更快
NVEC
高出72.9%
-49.9%
净利率更高
NVEC
高出114.7%
-60.3%
自由现金流更多
PLX
多$6.4M
$-4.8M
两年增速更快
NVEC
近两年复合增速
-6.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $9.1M |
| 净利润 | $3.4M | $-5.5M |
| 毛利率 | 78.6% | 49.4% |
| 营业利润率 | 60.2% | -51.1% |
| 净利率 | 54.4% | -60.3% |
| 营收同比 | 22.9% | -49.9% |
| 净利润同比 | 11.0% | -184.8% |
| 每股收益（稀释后） | $0.70 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NVECPLX
| Q4 25 | $6.2M | $9.1M | ||
| Q3 25 | $6.3M | $17.9M | ||
| Q2 25 | $6.1M | $15.7M | ||
| Q1 25 | $7.3M | $10.1M | ||
| Q4 24 | $5.1M | $18.2M | ||
| Q3 24 | $6.8M | $18.0M | ||
| Q2 24 | $6.8M | $13.5M | ||
| Q1 24 | $7.1M | — |
净利润NVECPLX
| Q4 25 | $3.4M | $-5.5M | ||
| Q3 25 | $3.3M | $2.4M | ||
| Q2 25 | $3.6M | $164.0K | ||
| Q1 25 | $3.9M | $-3.6M | ||
| Q4 24 | $3.0M | $6.5M | ||
| Q3 24 | $4.0M | $3.2M | ||
| Q2 24 | $4.1M | $-2.2M | ||
| Q1 24 | $3.8M | — |
毛利率NVECPLX
| Q4 25 | 78.6% | 49.4% | ||
| Q3 25 | 78.3% | 53.4% | ||
| Q2 25 | 80.6% | 62.5% | ||
| Q1 25 | 79.2% | 19.1% | ||
| Q4 24 | 84.2% | 78.7% | ||
| Q3 24 | 86.0% | 53.4% | ||
| Q2 24 | 85.6% | 29.8% | ||
| Q1 24 | 75.5% | — |
营业利润率NVECPLX
| Q4 25 | 60.2% | -51.1% | ||
| Q3 25 | 57.6% | 11.9% | ||
| Q2 25 | 62.0% | 7.5% | ||
| Q1 25 | 58.4% | -41.0% | ||
| Q4 24 | 58.5% | 39.6% | ||
| Q3 24 | 65.0% | 22.2% | ||
| Q2 24 | 64.7% | -18.0% | ||
| Q1 24 | 57.3% | — |
净利率NVECPLX
| Q4 25 | 54.4% | -60.3% | ||
| Q3 25 | 52.2% | 13.2% | ||
| Q2 25 | 58.6% | 1.0% | ||
| Q1 25 | 53.5% | -35.8% | ||
| Q4 24 | 60.2% | 35.6% | ||
| Q3 24 | 59.6% | 18.0% | ||
| Q2 24 | 60.4% | -16.4% | ||
| Q1 24 | 53.8% | — |
每股收益（稀释后）NVECPLX
| Q4 25 | $0.70 | $-0.06 | ||
| Q3 25 | $0.68 | $0.03 | ||
| Q2 25 | $0.74 | $0.00 | ||
| Q1 25 | $0.80 | $-0.05 | ||
| Q4 24 | $0.63 | $0.10 | ||
| Q3 24 | $0.83 | $0.03 | ||
| Q2 24 | $0.85 | $-0.03 | ||
| Q1 24 | $0.78 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.6M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $58.3M | $48.2M |
| 总资产 | $60.0M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NVECPLX
| Q4 25 | $20.6M | $14.7M | ||
| Q3 25 | $17.7M | $13.6M | ||
| Q2 25 | $15.8M | $17.9M | ||
| Q1 25 | $21.7M | $19.5M | ||
| Q4 24 | $20.4M | $19.8M | ||
| Q3 24 | $22.9M | $27.4M | ||
| Q2 24 | $21.7M | $23.4M | ||
| Q1 24 | $22.2M | — |
股东权益NVECPLX
| Q4 25 | $58.3M | $48.2M | ||
| Q3 25 | $59.7M | $52.9M | ||
| Q2 25 | $61.1M | $49.9M | ||
| Q1 25 | $62.3M | $45.2M | ||
| Q4 24 | $63.0M | $43.2M | ||
| Q3 24 | $64.9M | $32.4M | ||
| Q2 24 | $64.9M | $28.6M | ||
| Q1 24 | $65.6M | — |
总资产NVECPLX
| Q4 25 | $60.0M | $82.3M | ||
| Q3 25 | $61.5M | $82.3M | ||
| Q2 25 | $63.6M | $78.5M | ||
| Q1 25 | $64.3M | $73.9M | ||
| Q4 24 | $64.6M | $73.4M | ||
| Q3 24 | $65.9M | $61.6M | ||
| Q2 24 | $66.7M | $91.5M | ||
| Q1 24 | $66.8M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.2M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-4.8M | $1.6M |
| 自由现金流率自由现金流/营收 | -77.0% | 17.8% |
| 资本支出强度资本支出/营收 | 144.3% | 4.4% |
| 现金转化率经营现金流/净利润 | 1.24× | — |
| 过去12个月自由现金流最近4个季度 | $-5.5M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流NVECPLX
| Q4 25 | $4.2M | $2.0M | ||
| Q3 25 | $2.8M | $-3.7M | ||
| Q2 25 | $5.2M | $-5.2M | ||
| Q1 25 | $2.5M | $-5.1M | ||
| Q4 24 | $3.8M | $4.0M | ||
| Q3 24 | $2.1M | $4.1M | ||
| Q2 24 | $5.9M | $-3.6M | ||
| Q1 24 | $3.1M | — |
自由现金流NVECPLX
| Q4 25 | $-4.8M | $1.6M | ||
| Q3 25 | $2.7M | $-4.2M | ||
| Q2 25 | $4.1M | $-5.7M | ||
| Q1 25 | $-7.5M | $-5.4M | ||
| Q4 24 | $-6.3M | $3.6M | ||
| Q3 24 | $1.9M | $4.0M | ||
| Q2 24 | $4.9M | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率NVECPLX
| Q4 25 | -77.0% | 17.8% | ||
| Q3 25 | 42.9% | -23.7% | ||
| Q2 25 | 67.7% | -36.2% | ||
| Q1 25 | -103.7% | -53.0% | ||
| Q4 24 | -124.7% | 19.6% | ||
| Q3 24 | 28.5% | 22.4% | ||
| Q2 24 | 72.8% | -28.1% | ||
| Q1 24 | — | — |
资本支出强度NVECPLX
| Q4 25 | 144.3% | 4.4% | ||
| Q3 25 | 1.1% | 2.8% | ||
| Q2 25 | 17.3% | 2.8% | ||
| Q1 25 | 137.9% | 3.0% | ||
| Q4 24 | 200.6% | 2.3% | ||
| Q3 24 | 3.1% | 0.5% | ||
| Q2 24 | 13.5% | 1.3% | ||
| Q1 24 | 0.0% | — |
现金转化率NVECPLX
| Q4 25 | 1.24× | — | ||
| Q3 25 | 0.84× | -1.58× | ||
| Q2 25 | 1.45× | -31.91× | ||
| Q1 25 | 0.64× | — | ||
| Q4 24 | 1.26× | 0.61× | ||
| Q3 24 | 0.53× | 1.27× | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 0.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NVEC
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
